Diseases

BioAtla which is a global biotechnology company aiming to develop Conditionally Active Biologic protein Therapeutics announced the treatment of first patient in its clinical trial…
Read More...

Sangamo Therapeutics declared that the Medicines and Healthcare Products Regulatory Agency of the United Kingdom has extended Clinical Trial Authorization for enlisting subjects into…
Read More...

MabVax Therapeutics , a clinical-stage biotechnology company that aims to develop antibody-based products to address unattainable medical needs to treat cancer declared positive results…
Read More...

Second Genome which is considered a leader in the development of novel medicines derived from the human microbiome initiated four collaborations with key academic institutions to assess…
Read More...

Spruce Biosciences which is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders asserted the launch of its Congenital Adrenal Hyperplasia…
Read More...

OrthoSpin which is a portfolio company of the Trendlines Group declared that it had successfully completed a first-in-human case for smart, robotic external fixation system assuring…
Read More...

ENYO Pharma SA declared that it is strengthening its leadership team with the appointment of a VP Non-Clinical Development & Product Profiling. ENYO Pharma also confirms that its…
Read More...

ALung Technologies asserted that it has initiated enrolling patient in its VENT-AVOID Trial of the Hemolung RAS. The Minneapolis Heart Institute Foundation recently enrolled the first…
Read More...

Johnson and Johnson Medical Companies asserted that Acclarent,Inc which is a leader in developing minimally-invasive Ear, Nose and Throat technologies has sought clearance from the U.S…
Read More...

Houston-based company specializing in dental sleep medicine and sleep apnea treatment, The Center for Craniofacial & Dental Sleep Medicine (CFDSM) assured that it has sought FDA…
Read More...

Sierra Oncology which is a clinical stage drug development company aiming to further the DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today…
Read More...

Celltex Therapeutics Corporation asserted its authorization to conduct an investigational protocol which is a Phase II B Wellness Protocol Clinical Study on Rheumatoid Arthritis and…
Read More...

Aridis Pharmaceuticals applying proprietary technologies to curate novel anti-infectives and immunotherapies for infectious diseases proclaimed that it has created a Joint Venture with …
Read More...

Amgen asserted that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending a label variation for Neulasta…
Read More...

Abbott and Surmodics proclaimed having forayed into an agreement wherein Abbott will possess exclusive commercialization rights for Surmodic's Surveil drug-coated balloon to treat the…
Read More...

Longeveron asserted that its revolutionary Clinical Trial initiated to treat infants with Hypoplastic Left Heart Syndrome as the first patient received the treatment using the company's…
Read More...

Medical device company reinventing venous access using proprietary material technology designed to reduce thrombus accumulation, Access Vascular asserted that the Company has sought …
Read More...

Eli Lilly and Company proclaimed that the USFood and Drug Administration has sanctioned Verzenio (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based…
Read More...

PharmaCyte Biotech aiming to develop targeted cellular therapies for Cancer and diabetes using its signature  live-cell encapsulation technology, Cell-in-a-Box, announced that its…
Read More...

Therapy combinations, Biomarkers and the challenge of prayer coverage for CAR T-cell therapy are the topics selected for this year's special tissue on immuno-oncology in  Evidence-Based…
Read More...